title: Pulmonary surfactant augments cytotoxicity of silica nanoparticles: Studies on an in vitro air-blood barrier model.
abstract: The air-blood barrier is a very thin membrane of about 2.2 µm thickness and therefore represents an ideal portal of entry for nanoparticles to be used therapeutically in a regenerative medicine strategy. Until now, numerous studies using cellular airway models have been conducted in vitro in order to investigate the potential hazard of NPs. However, in most in vitro studies a crucial alveolar component has been neglected. Before aspirated NPs encounter the cellular air-blood barrier, they impinge on the alveolar surfactant layer (10-20 nm in thickness) that lines the entire alveolar surface. Thus, a prior interaction of NPs with pulmonary surfactant components will occur. In the present study we explored the impact of pulmonary surfactant on the cytotoxic potential of amorphous silica nanoparticles (aSNPs) using in vitro mono- and complex coculture models of the air-blood barrier. Furthermore, different surface functionalisations (plain-unmodified, amino, carboxylate) of the aSNPs were compared in order to study the impact of chemical surface properties on aSNP cytotoxicity in combination with lung surfactant. The alveolar epithelial cell line A549 was used in mono- and in coculture with the microvascular cell line ISO-HAS-1 in the form of different cytotoxicity assays (viability, membrane integrity, inflammatory responses such as IL-8 release). At a distinct concentration (100 µg/mL) aSNP-plain displayed the highest cytotoxicity and IL-8 release in monocultures of A549. aSNP-NH2 caused a slight toxic effect, whereas aSNP-COOH did not exhibit any cytotoxicity. In combination with lung surfactant, aSNP-plain revealed an increased cytotoxicity in monocultures of A549, aSNP-NH2 caused a slightly augmented toxic effect, whereas aSNP-COOH did not show any toxic alterations. A549 in coculture did not show any decreased toxicity (membrane integrity) for aSNP-plain in combination with lung surfactant. However, a significant augmented IL-8 release was observed, but no alterations in combination with lung surfactant. The augmented aSNP toxicity with surfactant in monocultures appears to depend on the chemical surface properties of the aSNPs. Reactive silanol groups seem to play a crucial role for an augmented toxicity of aSNPs. The A549 cells in the coculture seem to be more robust towards aSNPs, which might be a result of a higher differentiation and polarization state due the longer culture period.
authors.affiliation: Institute of Pathology, University Medical Center Mainz, Langenbeckstr. 1, 55101 Mainz, Germany.
authors.forename: Jennifer Y
authors.initials: JY
authors.lastname: Kasper
authors.affiliation: Institute of Pathology, University Medical Center Mainz, Langenbeckstr. 1, 55101 Mainz, Germany.
authors.forename: Lisa
authors.initials: L
authors.lastname: Feiden
authors.affiliation: Institute of Pathology, University Medical Center Mainz, Langenbeckstr. 1, 55101 Mainz, Germany.
authors.forename: Maria I
authors.initials: MI
authors.lastname: Hermanns
authors.affiliation: Fraunhofer ICT-IMM, Carl-Zeiss-Str. 18-20, 55129 Mainz, Germany.
authors.forename: Christoph
authors.initials: C
authors.lastname: Bantz
authors.affiliation: Fraunhofer ICT-IMM, Carl-Zeiss-Str. 18-20, 55129 Mainz, Germany.
authors.forename: Michael
authors.initials: M
authors.lastname: Maskos
authors.affiliation: Institute of Pathology, University Medical Center Mainz, Langenbeckstr. 1, 55101 Mainz, Germany.
authors.forename: Ronald E
authors.initials: RE
authors.lastname: Unger
authors.affiliation: Institute of Pathology, University Medical Center Mainz, Langenbeckstr. 1, 55101 Mainz, Germany.
authors.forename: C James
authors.initials: CJ
authors.lastname: Kirkpatrick
keywords: air–blood barrier; cytotoxicity; inflammatory response; pulmonary surfactant; silica nanoparticles
references.citation: Lab Invest. 2004 Jun;84(6):736-52
references.pmid: 15077120
references.citation: Int J Nanomedicine. 2011;6:3449-59
references.pmid: 22267929
references.citation: Environ Health Perspect. 1990 Jul;87:337-41
references.pmid: 2176590
references.citation: Int J Pharm. 2008 May 22;356(1-2):239-47
references.pmid: 18358652
references.citation: Microvasc Res. 2002 Nov;64(3):384-97
references.pmid: 12453433
references.citation: Vaccine. 2008 Jun 25;26(27-28):3389-94
references.pmid: 18511160
references.citation: Eur J Pharm Biopharm. 2013 Jun;84(2):275-87
references.pmid: 23183446
references.citation: Part Fibre Toxicol. 2013 Mar 25;10:6
references.pmid: 23531298
references.citation: Biomacromolecules. 2010 Nov 8;11(11):2836-9
references.pmid: 20961117
references.citation: J Am Chem Soc. 2012 Sep 26;134(38):15790-804
references.pmid: 22924492
references.citation: Part Fibre Toxicol. 2010 Dec 03;7(1):39
references.pmid: 21126379
references.citation: Anal Biochem. 1986 Nov 15;159(1):109-13
references.pmid: 3812988
references.citation: J Appl Physiol (1985). 2003 May;94(5):1793-801
references.pmid: 12547838
references.citation: Nat Nanotechnol. 2013 Oct;8(10):772-81
references.pmid: 24056901
references.citation: J Exp Med. 1966 Aug 1;124(2):141-54
references.pmid: 4288309
references.citation: Int J Pharm. 2012 Oct 15;436(1-2):778-85
references.pmid: 22884833
references.citation: Inhal Toxicol. 2009 Jul;21 Suppl 1:97-103
references.pmid: 19558240
references.citation: J R Soc Interface. 2010 Feb 6;7 Suppl 1:S41-54
references.pmid: 19793744
references.citation: Biomacromolecules. 2008 Feb;9(2):435-43
references.pmid: 18189360
references.citation: Nat Biotechnol. 2010 Dec;28(12):1275-6
references.pmid: 21139613
references.citation: PLoS One. 2010 Dec 31;5(12):e14476
references.pmid: 21217824
references.citation: Part Fibre Toxicol. 2010 Sep 11;7:25
references.pmid: 20831820
references.citation: Arch Toxicol. 2013 Jun;87(6):1053-65
references.pmid: 22669515
references.citation: Chem Res Toxicol. 2009 Jul;22(7):1359-68
references.pmid: 19580308
references.citation: J Nanobiotechnology. 2010 Dec 15;8:31
references.pmid: 21159192
references.citation: Int J Nanomedicine. 2012;7:5577-91
references.pmid: 23144561
references.citation: Part Fibre Toxicol. 2012 May 24;9:17
references.pmid: 22624622
references.citation: J Pharm Pharmacol. 2006 Nov;58(11):1491-8
references.pmid: 17132212
references.citation: Nano Lett. 2005 Feb;5(2):281-5
references.pmid: 15794611
references.citation: Respir Physiol. 1978 Feb;32(2):121-40
references.pmid: 644146
references.citation: Part Fibre Toxicol. 2011 Jan 27;8(1):6
references.pmid: 21272353
references.citation: J R Soc Interface. 2010 Feb 6;7 Suppl 1:S15-26
references.pmid: 19846443
references.citation: Nanotechnol Sci Appl. 2012 Sep 07;5:87-100
references.pmid: 24198499
references.citation: J Occup Environ Hyg. 2006 Dec;3(12):718-23
references.pmid: 17133693
references.citation: Int J Pharm. 2009 Nov 3;381(2):130-9
references.pmid: 19450671
references.citation: J Biol Chem. 2000 Aug 18;275(33):25130-8
references.pmid: 10833514
references.citation: Int J Cancer. 1999 Apr 12;81(2):305-8
references.pmid: 10188735
references.citation: Free Radic Biol Med. 2003 Jun 15;34(12):1507-16
references.pmid: 12788471
references.citation: Nanoscale. 2013 Jun 7;5(11):4870-83
references.pmid: 23619571